Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250408-00130
S Tang, W Hou, S J Zheng
Wilson disease (WD), also known as hepatolenticular degeneration, is an autosomal recessive inherited disorder of copper metabolism that primarily affects the liver, brain, and other organs. The diagnostic criteria include clinical features, biochemical tests (plasma ceruloplasmin, 24-hour urinary copper, liver copper content), and molecular genetic analysis. The Leipzig scoring system, supplemented by the use of exchangeable copper, is recommended for diagnosis. Pharmacotherapy mainly includes chelating agents (such as penicillamine and trientine) and zinc salts. Chelating agent therapy is recommended only for patients with severe liver disease. Patient monitoring is primarily based on clinical symptoms, liver biochemical indices, and copper metabolism parameters (such as 24-hour urinary copper and exchangeable copper) to identify poor adherence as well as over-treatment or under-treatment situations. The diagnosis and treatment of acute liver failure with WD is extremely challenging, as the diagnosis is difficult and medical treatment cannot save life. The role of liver transplantation has been clearly recognized in the treatment of acute liver failure with WD, and it may also be considered in cases with neurological involvement.
{"title":"[Recommendations from the European Association for the Study of the Liver and the European Reference Network for Rare Liver Diseases Clinical Practice Guidelines for hepatolenticular degeneration].","authors":"S Tang, W Hou, S J Zheng","doi":"10.3760/cma.j.cn501113-20250408-00130","DOIUrl":"10.3760/cma.j.cn501113-20250408-00130","url":null,"abstract":"<p><p>Wilson disease (WD), also known as hepatolenticular degeneration, is an autosomal recessive inherited disorder of copper metabolism that primarily affects the liver, brain, and other organs. The diagnostic criteria include clinical features, biochemical tests (plasma ceruloplasmin, 24-hour urinary copper, liver copper content), and molecular genetic analysis. The Leipzig scoring system, supplemented by the use of exchangeable copper, is recommended for diagnosis. Pharmacotherapy mainly includes chelating agents (such as penicillamine and trientine) and zinc salts. Chelating agent therapy is recommended only for patients with severe liver disease. Patient monitoring is primarily based on clinical symptoms, liver biochemical indices, and copper metabolism parameters (such as 24-hour urinary copper and exchangeable copper) to identify poor adherence as well as over-treatment or under-treatment situations. The diagnosis and treatment of acute liver failure with WD is extremely challenging, as the diagnosis is difficult and medical treatment cannot save life. The role of liver transplantation has been clearly recognized in the treatment of acute liver failure with WD, and it may also be considered in cases with neurological involvement.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"988-992"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250904-00368
C L Sun, S Y Chen, X N Wu, J L Zhou, T T Meng, B Q Wang, X Y Zhao, X J Ou, J D Jia, Y M Sun, H You
<p><p><b>Objective:</b> To investigate the role of dynamic changes in liver stiffness measurement (LSM) in predicting liver-related end-point events (LREs) occurrence in patients with chronic hepatitis B (CHB) with liver fibrosis during long-term antiviral therapy. <b>Methods:</b> Data were collected from CHB patients whose liver biopsy results showed Metavir fibrosis stage F2～F4 or clinically diagnosed cirrhosis. Entecavir antiviral therapy was mainly administered. Follow-up was conducted once every six months. Clinical data such as demographic information, blood routine tests, liver biochemical parameters, HBV virological and serological test results, and LSM were collected. Dynamic changes in LSM were categorized into four types based on LSM levels before treatment (0y) and following two years of antiviral therapy (2y) : (1) LSM<sub>0y</sub> < 10 kPa and LSM<sub>2y</sub> < 10 kPa, i.e., LSM persisted < 10 kPa; (2) LSM<sub>0y</sub> < 10 kPa and LSM<sub>2y</sub> ≥ 10 kPa, i.e., LSM increased to ≥ 10 kPa; (3) LSM<sub>0y</sub> ≥ 10 kPa and LSM<sub>2y</sub> < 10 kPa, i.e., LSM decreased to < 10 kPa; (4) LSM<sub>0y</sub> ≥ 10 kPa and LSM<sub>2y</sub> ≥ 10 kPa, i.e., LSM persisted ≥ 10 kPa. The predictive role of the dynamic changes of LSM in the occurrence of LREs was analyzed. The Wilcoxon rank-sum test was used for quantitative data. Fisher's exact test was used for categorical data. Multivariate analysis was performed using the Cox proportional hazards regression model. Survival curves were plotted and compared using the Kaplan-Meier. <b>Results:</b> A total of 713 CHB cases with liver fibrosis were included, among whom 512 had cirrhosis. The cumulative incidence of LREs following two years of antiviral therapy was low in patients with LSM<sub>0y</sub> < 10 kPa during follow-up (all patients: LSM persisted < 10 kPa 1.6% vs. LSM increased to ≥ 10 kPa 0%; cirrhosis subgroup: LSM persisted < 10 kPa 0% vs. LSM increased to ≥ 10 kPa 0%). The 5-year cumulative incidence of LREs following two years of antiviral treatment was significantly higher in patients with LSM0y ≥ 10 kPa than in those with LSM persisting ≥ 10 kPa and those with LSM decreasing to < 10 kPa during follow-up (all patients: LSM persisted ≥ 10 kPa 12.4% vs. LSM decreased to < 10 kPa 3.6%; cirrhosis subgroup: LSM persisted ≥ 10 kPa 12.6% vs. LSM decreased to < 10 kPa 4.3%). Patients with LSM persisting at ≥ 10 kPa had a significantly increased risk of LREs following two years of antiviral treatment compared with those whose LSM decreased to <10 kPa during follow-up after adjusting for age, gender, baseline body mass index, platelet count, and alanine aminotransferase (all patients, aHR=2.96, 95% <i>CI</i>: 1.41～6.24, <i>P</i>=0.005; cirrhosis subgroup, aHR=2.74, 95% <i>CI</i>:1.26～5.95, <i>P</i>=0.011). <b>Conclusions:</b> LSM<10 kPa before antiviral treatment had a lower risk of liver-related endpoint events following two years of treatment among CHB patients with liver fibrosis. LSM ≥1
{"title":"[Predictive role of dynamic changes in liver stiffness measurement for liver-related endpoint events in chronic hepatitis B].","authors":"C L Sun, S Y Chen, X N Wu, J L Zhou, T T Meng, B Q Wang, X Y Zhao, X J Ou, J D Jia, Y M Sun, H You","doi":"10.3760/cma.j.cn501113-20250904-00368","DOIUrl":"10.3760/cma.j.cn501113-20250904-00368","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the role of dynamic changes in liver stiffness measurement (LSM) in predicting liver-related end-point events (LREs) occurrence in patients with chronic hepatitis B (CHB) with liver fibrosis during long-term antiviral therapy. <b>Methods:</b> Data were collected from CHB patients whose liver biopsy results showed Metavir fibrosis stage F2～F4 or clinically diagnosed cirrhosis. Entecavir antiviral therapy was mainly administered. Follow-up was conducted once every six months. Clinical data such as demographic information, blood routine tests, liver biochemical parameters, HBV virological and serological test results, and LSM were collected. Dynamic changes in LSM were categorized into four types based on LSM levels before treatment (0y) and following two years of antiviral therapy (2y) : (1) LSM<sub>0y</sub> < 10 kPa and LSM<sub>2y</sub> < 10 kPa, i.e., LSM persisted < 10 kPa; (2) LSM<sub>0y</sub> < 10 kPa and LSM<sub>2y</sub> ≥ 10 kPa, i.e., LSM increased to ≥ 10 kPa; (3) LSM<sub>0y</sub> ≥ 10 kPa and LSM<sub>2y</sub> < 10 kPa, i.e., LSM decreased to < 10 kPa; (4) LSM<sub>0y</sub> ≥ 10 kPa and LSM<sub>2y</sub> ≥ 10 kPa, i.e., LSM persisted ≥ 10 kPa. The predictive role of the dynamic changes of LSM in the occurrence of LREs was analyzed. The Wilcoxon rank-sum test was used for quantitative data. Fisher's exact test was used for categorical data. Multivariate analysis was performed using the Cox proportional hazards regression model. Survival curves were plotted and compared using the Kaplan-Meier. <b>Results:</b> A total of 713 CHB cases with liver fibrosis were included, among whom 512 had cirrhosis. The cumulative incidence of LREs following two years of antiviral therapy was low in patients with LSM<sub>0y</sub> < 10 kPa during follow-up (all patients: LSM persisted < 10 kPa 1.6% vs. LSM increased to ≥ 10 kPa 0%; cirrhosis subgroup: LSM persisted < 10 kPa 0% vs. LSM increased to ≥ 10 kPa 0%). The 5-year cumulative incidence of LREs following two years of antiviral treatment was significantly higher in patients with LSM0y ≥ 10 kPa than in those with LSM persisting ≥ 10 kPa and those with LSM decreasing to < 10 kPa during follow-up (all patients: LSM persisted ≥ 10 kPa 12.4% vs. LSM decreased to < 10 kPa 3.6%; cirrhosis subgroup: LSM persisted ≥ 10 kPa 12.6% vs. LSM decreased to < 10 kPa 4.3%). Patients with LSM persisting at ≥ 10 kPa had a significantly increased risk of LREs following two years of antiviral treatment compared with those whose LSM decreased to <10 kPa during follow-up after adjusting for age, gender, baseline body mass index, platelet count, and alanine aminotransferase (all patients, aHR=2.96, 95% <i>CI</i>: 1.41～6.24, <i>P</i>=0.005; cirrhosis subgroup, aHR=2.74, 95% <i>CI</i>:1.26～5.95, <i>P</i>=0.011). <b>Conclusions:</b> LSM<10 kPa before antiviral treatment had a lower risk of liver-related endpoint events following two years of treatment among CHB patients with liver fibrosis. LSM ≥1","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"993-1000"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250726-00295
P S Xu, M C Wang, J J Chen, H Y Wang
Portal hypertension is a major complication of cirrhosis. The current gold standard for diagnosis is the hepatic venous pressure gradient, but it possesses limitations such as invasiveness. In recent years, non-invasive tests have made significant progress in terms of evaluating and prognostication of portal hypertension. This article reviews the diagnostic value and related research advancements of different non-invasive tests in assessing portal hypertension in patients with cirrhosis.
{"title":"[Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome].","authors":"P S Xu, M C Wang, J J Chen, H Y Wang","doi":"10.3760/cma.j.cn501113-20250726-00295","DOIUrl":"10.3760/cma.j.cn501113-20250726-00295","url":null,"abstract":"<p><p>Portal hypertension is a major complication of cirrhosis. The current gold standard for diagnosis is the hepatic venous pressure gradient, but it possesses limitations such as invasiveness. In recent years, non-invasive tests have made significant progress in terms of evaluating and prognostication of portal hypertension. This article reviews the diagnostic value and related research advancements of different non-invasive tests in assessing portal hypertension in patients with cirrhosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"928-933"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250515-00188
Dilnar Ibrahim, X B Lu
Liver injury, as one of the common clinical manifestations of brucellosis, presents a diversity of pathophysiological mechanisms, pathological manifestations, and clinical features, which may trigger severe organ dysfunction and poor prognostic conditions. This article systematically analyzes the research progress on brucellosis combined with liver injury at home and abroad, focusing on discussing its pathophysiological mechanism, pathological and clinical features, as well as prognostic outcomes, with the aim to provide a solid theoretical basis for the clinical diagnosis, therapeutic strategies, and prognostic management.
{"title":"[Research progress on brucellosis combined with liver injury].","authors":"Dilnar Ibrahim, X B Lu","doi":"10.3760/cma.j.cn501113-20250515-00188","DOIUrl":"10.3760/cma.j.cn501113-20250515-00188","url":null,"abstract":"<p><p>Liver injury, as one of the common clinical manifestations of brucellosis, presents a diversity of pathophysiological mechanisms, pathological manifestations, and clinical features, which may trigger severe organ dysfunction and poor prognostic conditions. This article systematically analyzes the research progress on brucellosis combined with liver injury at home and abroad, focusing on discussing its pathophysiological mechanism, pathological and clinical features, as well as prognostic outcomes, with the aim to provide a solid theoretical basis for the clinical diagnosis, therapeutic strategies, and prognostic management.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"1009-1014"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250812-00323
X Y Zhao, Y M Sun, Y K Gao, Z Z Lu, C Huang, Y Y Kong, J D Jia, H You
Liver fibrosis is a key histologic marker of long-term outcome in chronic liver disease. Non-invasive tests (NITs) have been shown to have predictive value, but the superiority of "dynamic" versus "static" assessment remains controversial. This article systematically reviews the latest evidence to elucidate the association between longitudinal changes in NITs and hepatic adverse events and assess the incremental contribution of dynamic monitoring to the model. Additionally, it reveals that the dynamic monitoring of NITs is truly superior to single evaluation, but the evidence is limited and the heterogeneity is significant. Dynamic modeling approaches for NITs require a shift from traditional parameter estimation to time-series machine learning. Future studies should make breakthroughs in disease stratification, modeling method innovation, data quality improvement, and prediction ability assessment so as to promote the transition of NITs from "static risk label" to "dynamic individualized engine," which can truly serve clinical decision-making.
{"title":"[Real-time or dynamic non-invasive liver fibrosis testing for evaluating clinical prognoses and predicting chronic liver disease].","authors":"X Y Zhao, Y M Sun, Y K Gao, Z Z Lu, C Huang, Y Y Kong, J D Jia, H You","doi":"10.3760/cma.j.cn501113-20250812-00323","DOIUrl":"10.3760/cma.j.cn501113-20250812-00323","url":null,"abstract":"<p><p>Liver fibrosis is a key histologic marker of long-term outcome in chronic liver disease. Non-invasive tests (NITs) have been shown to have predictive value, but the superiority of \"dynamic\" versus \"static\" assessment remains controversial. This article systematically reviews the latest evidence to elucidate the association between longitudinal changes in NITs and hepatic adverse events and assess the incremental contribution of dynamic monitoring to the model. Additionally, it reveals that the dynamic monitoring of NITs is truly superior to single evaluation, but the evidence is limited and the heterogeneity is significant. Dynamic modeling approaches for NITs require a shift from traditional parameter estimation to time-series machine learning. Future studies should make breakthroughs in disease stratification, modeling method innovation, data quality improvement, and prediction ability assessment so as to promote the transition of NITs from \"static risk label\" to \"dynamic individualized engine,\" which can truly serve clinical decision-making.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"945-949"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250710-00272
Q C Ge, L G Lu
Liver fibrosis is a common pathological process in various chronic liver diseases. Early-stage and accurate diagnosis, as well as assessment of the degree of liver fibrosis, is crucial for the management of chronic liver diseases. Conventional imaging techniques for liver fibrosis (elastography and magnetic resonance elastography) still have the drawback of low sensitivity in detecting early-stage fibrosis. In recent years, emerging imaging omics based on ultrasound and magnetic resonance have improved the diagnostic accuracy and visualization stage of liver fibrosis. The emergence of artificial intelligence technology has also provided more options for the technological advancement of liver fibrosis imaging. This article aims to review the emerging liver fibrosis imaging technologies in recent years and compare their diagnostic performance with ultrasound elastography, shear wave elastography, and magnetic resonance elastography recommended by the current domestic and international guidelines and to pinpoint simultaneously the limitations and challenges that still exist in liver fibrosis imaging while reflecting the technological advances.
{"title":"[Advances and challenges in new technologies for imaging evaluation of liver fibrosis].","authors":"Q C Ge, L G Lu","doi":"10.3760/cma.j.cn501113-20250710-00272","DOIUrl":"10.3760/cma.j.cn501113-20250710-00272","url":null,"abstract":"<p><p>Liver fibrosis is a common pathological process in various chronic liver diseases. Early-stage and accurate diagnosis, as well as assessment of the degree of liver fibrosis, is crucial for the management of chronic liver diseases. Conventional imaging techniques for liver fibrosis (elastography and magnetic resonance elastography) still have the drawback of low sensitivity in detecting early-stage fibrosis. In recent years, emerging imaging omics based on ultrasound and magnetic resonance have improved the diagnostic accuracy and visualization stage of liver fibrosis. The emergence of artificial intelligence technology has also provided more options for the technological advancement of liver fibrosis imaging. This article aims to review the emerging liver fibrosis imaging technologies in recent years and compare their diagnostic performance with ultrasound elastography, shear wave elastography, and magnetic resonance elastography recommended by the current domestic and international guidelines and to pinpoint simultaneously the limitations and challenges that still exist in liver fibrosis imaging while reflecting the technological advances.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"923-927"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250809-00322
R Jin, W J Ni, F J Rui, J Li
Liver fibrosis is a key pathological process in the progression of chronic liver disease, and its early stage and accurate diagnosis are crucial for improving patient prognosis. In recent years, the non-invasive diagnosis of liver fibrosis has gradually shifted from the traditional model based on conventional serological indicators to an evaluation system that integrates new biomarkers and multi-omics technologies. This article systematically reviews the evolution of the serological evaluation system for non-invasive diagnosis of liver fibrosis, introduces the application progress of serological models, novel biomarkers, and the introduction of multimodal integration and artificial intelligence technology, and analyzes their advantages and limitations, with aim of providing novel ideas for achieving accurate diagnosis and assisting in clinical management of patients.
{"title":"[Clinical practice and challenges from simple models to precise integration for serological evaluation of a non-invasive diagnosis of liver fibrosis].","authors":"R Jin, W J Ni, F J Rui, J Li","doi":"10.3760/cma.j.cn501113-20250809-00322","DOIUrl":"10.3760/cma.j.cn501113-20250809-00322","url":null,"abstract":"<p><p>Liver fibrosis is a key pathological process in the progression of chronic liver disease, and its early stage and accurate diagnosis are crucial for improving patient prognosis. In recent years, the non-invasive diagnosis of liver fibrosis has gradually shifted from the traditional model based on conventional serological indicators to an evaluation system that integrates new biomarkers and multi-omics technologies. This article systematically reviews the evolution of the serological evaluation system for non-invasive diagnosis of liver fibrosis, introduces the application progress of serological models, novel biomarkers, and the introduction of multimodal integration and artificial intelligence technology, and analyzes their advantages and limitations, with aim of providing novel ideas for achieving accurate diagnosis and assisting in clinical management of patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"934-944"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250825-00346
P P Lai, S Y Chen, Y M Sun, H You
Liver fibrosis is a common pathological process associated with multiple chronic liver diseases. Recent advancements have significantly improved the non-invasive assessment of liver fibrosis. This article focuses on the exploration of hot topics, namely how noninvasive indicators can evaluate liver fibrosis reversal and predict clinical outcomes. Concurrently, it indicates that attention should be paid to the dynamic changes of noninvasive indicators, and population screening efforts should be strengthened to achieve early diagnosis and treatment of liver fibrosis so as to improve long-term clinical outcomes.
{"title":"[Non-invasive assessment of liver fibrosis: prioritizing dynamic monitoring and expanding population screening].","authors":"P P Lai, S Y Chen, Y M Sun, H You","doi":"10.3760/cma.j.cn501113-20250825-00346","DOIUrl":"10.3760/cma.j.cn501113-20250825-00346","url":null,"abstract":"<p><p>Liver fibrosis is a common pathological process associated with multiple chronic liver diseases. Recent advancements have significantly improved the non-invasive assessment of liver fibrosis. This article focuses on the exploration of hot topics, namely how noninvasive indicators can evaluate liver fibrosis reversal and predict clinical outcomes. Concurrently, it indicates that attention should be paid to the dynamic changes of noninvasive indicators, and population screening efforts should be strengthened to achieve early diagnosis and treatment of liver fibrosis so as to improve long-term clinical outcomes.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"919-922"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20241017-00546
Z N Wu, Z Q Qi, Y Xiao, T Y Guo, H Tong, Y D Wang
The formation of portal vein thrombosis (PVT) is one of the complications of liver cirrhosis, which is easily overlooked but is not uncommon. With the deepening research on PVT in liver cirrhosis, evidence regarding the assessment of PVT formation, treatment effectiveness, and prognostic outcomes is continually being updated. This article summarizes recent studies on predicting the formation, anticoagulation efficacy, and survival models; analyzes and evaluates the rationality, standardization, and practicality of prediction models; and compares their strengths and weaknesses to provide a reference for clinicians in the individualized management and treatment of PVT in patients with liver cirrhosis.
{"title":"[Research progress on predictive models of portal vein thrombosis in liver cirrhosis].","authors":"Z N Wu, Z Q Qi, Y Xiao, T Y Guo, H Tong, Y D Wang","doi":"10.3760/cma.j.cn501113-20241017-00546","DOIUrl":"10.3760/cma.j.cn501113-20241017-00546","url":null,"abstract":"<p><p>The formation of portal vein thrombosis (PVT) is one of the complications of liver cirrhosis, which is easily overlooked but is not uncommon. With the deepening research on PVT in liver cirrhosis, evidence regarding the assessment of PVT formation, treatment effectiveness, and prognostic outcomes is continually being updated. This article summarizes recent studies on predicting the formation, anticoagulation efficacy, and survival models; analyzes and evaluates the rationality, standardization, and practicality of prediction models; and compares their strengths and weaknesses to provide a reference for clinicians in the individualized management and treatment of PVT in patients with liver cirrhosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"1015-1020"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.3760/cma.j.cn501113-20250728-00298
The Chinese Society of Hepatology of the Chinese Medical Association has invited experts in relevant fields to revise and rename the 2019 "Chinese guidelines on the management of liver cirrhosis" to "Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)". The guidelines put forward the recommendations for the clinical diagnosis and management of cirrhosis in the compensation, decompensation, and re-compensation stages, as well as for cirrhosis reversal and related complications.
{"title":"[Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)].","authors":"","doi":"10.3760/cma.j.cn501113-20250728-00298","DOIUrl":"10.3760/cma.j.cn501113-20250728-00298","url":null,"abstract":"<p><p>The Chinese Society of Hepatology of the Chinese Medical Association has invited experts in relevant fields to revise and rename the 2019 \"Chinese guidelines on the management of liver cirrhosis\" to \"Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)\". The guidelines put forward the recommendations for the clinical diagnosis and management of cirrhosis in the compensation, decompensation, and re-compensation stages, as well as for cirrhosis reversal and related complications.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"958-976"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号